Circulating tumor markers in the monitoring of gynecologic malignancies

P. E. Schwartz, Setsuko K Chambers, J. T. Chambers, J. Gutmann, N. Katopodis, R. Foemmel

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Plasma from 262 patients with gynecologic malignancies was assayed for levels of circulating tumor markers (CA 125, LSA [lipid associated sialic acid in plasma, LASA-P (Dianon Systems, Inc., Stratford, CT)], CA 19-9, and carcinoembryonic antigen [CEA]) and correlated with the patients' clinical status. In the patients with ovarian cancer the sensitivities of LSA and CA 125 for patients with clinical evidence of disease were 71% and 76% respectively; the specificities for patients with no clinical evidence of disease were 90% and 86% respectively. Using both tumor markers, a sensitivity of 84% and specificity of 85% was obtained. Additionally, CA 125 was elevated in 59% of patients with clinically advanced or recurrent endometrial cancer, and LSA was elevated in 63% of patients with clinical evidence of cervical cancer. Neither CEA nor CA 19-9 levels correlated with clinical status in patients with ovarian or cervical cancer. The values of CA 125 and LSA were examined in relation to the findings at second-look surgery in patients with ovarian cancer. Absence of elevated tumor markers does not obviate the need for second-look surgery; the false negative rate for CA 125 was 40% (6/15). However, the finding of two elevated plasma markers 1 month or more apart, in ovarian cancer patients who were clinically free of disease, was strongly suggestive of recurrent cancer; 13 of 14 such patients showed this association. This latter finding may help to identify a group of patients in whom early surgical intervention is indicated.

Original languageEnglish (US)
Pages (from-to)353-361
Number of pages9
JournalCancer
Volume60
Issue number3
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Tumor Biomarkers
Neoplasms
Ovarian Neoplasms
Second-Look Surgery
Carcinoembryonic Antigen
Uterine Cervical Neoplasms
CA-19-9 Antigen
Endometrial Neoplasms
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Circulating tumor markers in the monitoring of gynecologic malignancies. / Schwartz, P. E.; Chambers, Setsuko K; Chambers, J. T.; Gutmann, J.; Katopodis, N.; Foemmel, R.

In: Cancer, Vol. 60, No. 3, 1987, p. 353-361.

Research output: Contribution to journalArticle

Schwartz, P. E. ; Chambers, Setsuko K ; Chambers, J. T. ; Gutmann, J. ; Katopodis, N. ; Foemmel, R. / Circulating tumor markers in the monitoring of gynecologic malignancies. In: Cancer. 1987 ; Vol. 60, No. 3. pp. 353-361.
@article{a8e4e52ef5da4d2e8277f2cc77145018,
title = "Circulating tumor markers in the monitoring of gynecologic malignancies",
abstract = "Plasma from 262 patients with gynecologic malignancies was assayed for levels of circulating tumor markers (CA 125, LSA [lipid associated sialic acid in plasma, LASA-P (Dianon Systems, Inc., Stratford, CT)], CA 19-9, and carcinoembryonic antigen [CEA]) and correlated with the patients' clinical status. In the patients with ovarian cancer the sensitivities of LSA and CA 125 for patients with clinical evidence of disease were 71{\%} and 76{\%} respectively; the specificities for patients with no clinical evidence of disease were 90{\%} and 86{\%} respectively. Using both tumor markers, a sensitivity of 84{\%} and specificity of 85{\%} was obtained. Additionally, CA 125 was elevated in 59{\%} of patients with clinically advanced or recurrent endometrial cancer, and LSA was elevated in 63{\%} of patients with clinical evidence of cervical cancer. Neither CEA nor CA 19-9 levels correlated with clinical status in patients with ovarian or cervical cancer. The values of CA 125 and LSA were examined in relation to the findings at second-look surgery in patients with ovarian cancer. Absence of elevated tumor markers does not obviate the need for second-look surgery; the false negative rate for CA 125 was 40{\%} (6/15). However, the finding of two elevated plasma markers 1 month or more apart, in ovarian cancer patients who were clinically free of disease, was strongly suggestive of recurrent cancer; 13 of 14 such patients showed this association. This latter finding may help to identify a group of patients in whom early surgical intervention is indicated.",
author = "Schwartz, {P. E.} and Chambers, {Setsuko K} and Chambers, {J. T.} and J. Gutmann and N. Katopodis and R. Foemmel",
year = "1987",
doi = "10.1002/1097-0142(19870801)60:3<353::AID-CNCR2820600312>3.0.CO;2-V",
language = "English (US)",
volume = "60",
pages = "353--361",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Circulating tumor markers in the monitoring of gynecologic malignancies

AU - Schwartz, P. E.

AU - Chambers, Setsuko K

AU - Chambers, J. T.

AU - Gutmann, J.

AU - Katopodis, N.

AU - Foemmel, R.

PY - 1987

Y1 - 1987

N2 - Plasma from 262 patients with gynecologic malignancies was assayed for levels of circulating tumor markers (CA 125, LSA [lipid associated sialic acid in plasma, LASA-P (Dianon Systems, Inc., Stratford, CT)], CA 19-9, and carcinoembryonic antigen [CEA]) and correlated with the patients' clinical status. In the patients with ovarian cancer the sensitivities of LSA and CA 125 for patients with clinical evidence of disease were 71% and 76% respectively; the specificities for patients with no clinical evidence of disease were 90% and 86% respectively. Using both tumor markers, a sensitivity of 84% and specificity of 85% was obtained. Additionally, CA 125 was elevated in 59% of patients with clinically advanced or recurrent endometrial cancer, and LSA was elevated in 63% of patients with clinical evidence of cervical cancer. Neither CEA nor CA 19-9 levels correlated with clinical status in patients with ovarian or cervical cancer. The values of CA 125 and LSA were examined in relation to the findings at second-look surgery in patients with ovarian cancer. Absence of elevated tumor markers does not obviate the need for second-look surgery; the false negative rate for CA 125 was 40% (6/15). However, the finding of two elevated plasma markers 1 month or more apart, in ovarian cancer patients who were clinically free of disease, was strongly suggestive of recurrent cancer; 13 of 14 such patients showed this association. This latter finding may help to identify a group of patients in whom early surgical intervention is indicated.

AB - Plasma from 262 patients with gynecologic malignancies was assayed for levels of circulating tumor markers (CA 125, LSA [lipid associated sialic acid in plasma, LASA-P (Dianon Systems, Inc., Stratford, CT)], CA 19-9, and carcinoembryonic antigen [CEA]) and correlated with the patients' clinical status. In the patients with ovarian cancer the sensitivities of LSA and CA 125 for patients with clinical evidence of disease were 71% and 76% respectively; the specificities for patients with no clinical evidence of disease were 90% and 86% respectively. Using both tumor markers, a sensitivity of 84% and specificity of 85% was obtained. Additionally, CA 125 was elevated in 59% of patients with clinically advanced or recurrent endometrial cancer, and LSA was elevated in 63% of patients with clinical evidence of cervical cancer. Neither CEA nor CA 19-9 levels correlated with clinical status in patients with ovarian or cervical cancer. The values of CA 125 and LSA were examined in relation to the findings at second-look surgery in patients with ovarian cancer. Absence of elevated tumor markers does not obviate the need for second-look surgery; the false negative rate for CA 125 was 40% (6/15). However, the finding of two elevated plasma markers 1 month or more apart, in ovarian cancer patients who were clinically free of disease, was strongly suggestive of recurrent cancer; 13 of 14 such patients showed this association. This latter finding may help to identify a group of patients in whom early surgical intervention is indicated.

UR - http://www.scopus.com/inward/record.url?scp=0023229316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023229316&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19870801)60:3<353::AID-CNCR2820600312>3.0.CO;2-V

DO - 10.1002/1097-0142(19870801)60:3<353::AID-CNCR2820600312>3.0.CO;2-V

M3 - Article

C2 - 3594371

AN - SCOPUS:0023229316

VL - 60

SP - 353

EP - 361

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -